Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

被引：0

作者：

Yue-qin Wang

Ai-jun Shen

Jing-ya Sun

Xin Wang

Hong-chun Liu

Min-min Zhang

Dan-qi Chen

Bing Xiong

Jing-kang Shen

Mei-yu Geng

Min Zheng

Jian Ding

机构：

[1] China Pharmaceutical University,Department of New Drug Screening Center

[2] Division of Anti-tumor Pharmacology,Department of Thoracic Surgery

[3] Synthetic Organic and Medicinal Chemistry Laboratory,undefined

[4] State Key Laboratory of Drug Research,undefined

[5] Shanghai Institute of Materia Medica,undefined

[6] Chinese Academy of Sciences,undefined

[7] Shanghai Tongren Hospital,undefined

[8] Shanghai Jiao Tong University School of Medicine,undefined

来源：

Acta Pharmacologica Sinica | 2016年 / 37卷

关键词：

non-small cell lung cancer; gefitinib resistance; Hsp90;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1587 / 1596

页数：9

共 50 条

[41] Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Costa, Daniel B.
Kobayashi, Susumu
Tenen, Daniel G.
Huberman, Mark S.
LUNG CANCER, 2007, 58 (01) : 95 - 103
[42] The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants
Toyooka, Shinichi
Uchida, Akiko
Shigematsu, Hisayuki
Soh, Junichi
Ogino, Atsuko
Takata, Minoru
Kiura, Katsuyuki
Ouchida, Mamoru
Kosaka, Takayuki
Aoe, Motoi
Mitsudomi, Tetsuya
Date, Hiroshi
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 321 - 324
[43] Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
Yeung, Yiu To
Yin, Shuying
Lu, Bingbing
Fan, Suyu
Yang, Ran
Bai, Ruihua
Zhang, Chengjuan
Bode, Ann M.
Liu, Kangdong
Dong, Zigang
EBIOMEDICINE, 2018, 28 : 51 - 61
[44] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, Kyoko
Hata, Akito
Takeshita, Jumpei
Okuda, Chiyuki
Kaji, Reiko
Masago, Katsuhiro
Fujita, Shiro
Katakami, Nobuyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
[45] Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines
Li, Zi-Xuan
Qu, Lian-Yue
Hi-Wen
Zhong, Hong-Shan
Xu, Ke
Qiu, Xue-Shan
Wang, En-Hua
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (10): : 7304 - 7311
[46] Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET
Lee, Jin-Young
Kang, Bok Yun
Jung, Sang-Jin
Kwak, Ah-Won
Lee, Seung-On
Park, Jin Woo
Joo, Sang Hoon
Yoon, Goo
Lee, Mee-Hyun
Shim, Jung-Hyun
BIOMOLECULES & THERAPEUTICS, 2023, 31 (02) : 200 - 209
[47] EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells
Sugita, Shohei
Ito, Kentaro
Yamashiro, Yutaro
Moriya, Shota
Che, Xiao-Fang
Yokoyama, Tomohisa
Hiramoto, Masaki
Miyazawa, Keisuke
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 461 (01) : 28 - 34
[48] Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis
Koizumi, Hitomi
Yamada, Tadaaki
Takeuchi, Shinji
Nakagawa, Takayuki
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Yano, Seiji
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : 1078 - 1085
[49] Novel matrinic acid derivatives bearing 2-anilinothiazole structure for non-small cell lung cancer treatment with improved Hsp90 targeting effect
Xu, Yiming
Zeng, Panke
Wang, Haodong
Han, Keyan
Qiu, Gan
Wei, Yongquan
Chen, Rui
Wang, Lisheng
Liu, Xu
DRUG DEVELOPMENT RESEARCH, 2022, 83 (06) : 1434 - 1454
[50] Gefitinib (Iressa) trials in non-small cell lung cancer
Johnson, DH
LUNG CANCER, 2003, 41 : S23 - S28

← 1 2 3 4 5 →